**DRUG NAME:** Doxorubicin

**SYNONYM(S):** ADR, Adria, Dox, hydroxyl daunorubicin, NSC-123127

**COMMON TRADE NAME(S):** generic available, ADRIAMYCIN®, RUBEX® (USA)

**CLASSIFICATION:** anthracycline antineoplastic antibiotic

*Special pediatric considerations are noted when applicable, otherwise adult provisions apply.*

**MECHANISM OF ACTION:**

Doxorubicin binds directly to DNA via intercalation between base pairs on the DNA helix. Doxorubicin also inhibits DNA repair by inhibiting topoisomerase II. These actions result in the blockade of DNA and RNA synthesis and fragmentation of DNA. Doxorubicin is also a powerful iron-chelator. The iron-doxorubicin complex can bind DNA and cell membranes producing free radicals that immediately cleave DNA and cell membranes. Although maximally cytotoxic in S phase, doxorubicin is not cell cycle-specific.

**PHARMACOKINETICS:**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interpatient variability</td>
<td>clearance reduced in obese patients (i.e., &gt;130% ideal body weight)</td>
</tr>
<tr>
<td>Oral Absorption</td>
<td>not stable in gastric acids; not absorbed from GI tract</td>
</tr>
<tr>
<td>Distribution</td>
<td>widely distributed in plasma and in tissues</td>
</tr>
<tr>
<td></td>
<td>cross blood brain barrier? no</td>
</tr>
<tr>
<td></td>
<td>volume of distribution² 25 L/kg</td>
</tr>
<tr>
<td></td>
<td>plasma protein binding⁴ 70%</td>
</tr>
<tr>
<td>Metabolism</td>
<td>in the liver and other tissues by an aldo-keto reductase enzyme</td>
</tr>
<tr>
<td></td>
<td>active metabolite doxorubicin</td>
</tr>
<tr>
<td></td>
<td>inactive metabolite(s) doxorubicinone, aglycones and conjugates</td>
</tr>
<tr>
<td>Excretion</td>
<td>predominantly in bile</td>
</tr>
<tr>
<td></td>
<td>urine⁴ 3-10% as metabolites</td>
</tr>
<tr>
<td></td>
<td>feces⁴ 40-50% as unchanged drug</td>
</tr>
<tr>
<td></td>
<td>terminal half life⁸ 20-48 h</td>
</tr>
<tr>
<td></td>
<td>clearance⁹ 27.5-59.6 L/h/m²</td>
</tr>
<tr>
<td>Gender</td>
<td>terminal half life⁴: male 54 h; female 35 h</td>
</tr>
<tr>
<td></td>
<td>clearance⁴: male 113 L/h; female 44 L/h</td>
</tr>
<tr>
<td>Children</td>
<td>increased risk for delayed cardiotoxicity⁴</td>
</tr>
</tbody>
</table>

Adapted from standard reference³ unless specified otherwise.
USES:

**Primary uses:**
- Bladder carcinoma
- Breast cancer
- Endocrine carcinoma
- Ewing's sarcoma
- Gastric cancer
- Gynecological carcinoma
- Head and neck cancer
- Hepatic carcinoma
- Hepatoma
- Kaposi's sarcoma
- Leukemia, acute lymphoblastic
- Leukemia, acute myeloblastic
- Lung cancer
- Lymphoma, Hodgkin's
- Lymphoma, non-Hodgkin's
- Neuroblastomas
- Osteosarcoma
- Pancreatic cancer
- Sarcoma, soft tissue
- Testicular carcinoma
- Thyroid carcinoma
- Urothelial carcinoma
- Wilm's tumour

**Other uses:**
- Multiple myeloma
- Prostate cancer
- Thymoma

*S* indicates Health Canada approved indication

SPECIAL PRECAUTIONS:

**Contraindicated** in patients with the following conditions:
- Hypersensitivity to doxorubicin or any component of the product
- Hypersensitivity to other anthracyclines (e.g., epirubicin, daunorubicin)
- Hypersensitivity to anthracenediones (e.g., mitoxantrone, mitomycin)
- Severe hepatic impairment
- Severe myocardial insufficiency
- Recent myocardial infarction
- Severe arrhythmias
- History of severe cardiac disease
- Previous therapy with high cumulative doses of anthracyclines (e.g., doxorubicin, daunorubicin, epirubicin, idarubicin)
- Previous therapy with high cumulative doses of some anthracenediones (e.g., mitoxantrone)

**Cardiac toxicity** is a risk of doxorubicin therapy that may be manifested by early (acute) or late (delayed) effects. Cardiac function should be assessed at baseline and continue during treatment; refer to Side Effects section for more information. Risk factors for developing doxorubicin-induced cardiotoxicity include:
- High cumulative dose, previous therapy with other anthracyclines or anthracenediones
- Prior or concomitant radiotherapy to the mediastinal/pericardial area
- Pre-existing heart disease
- Extremes of age
- Liver disease
- Concomitant chemotherapy, especially bevacizumab, cyclophosphamide, PACLitaxel, and trastuzumab
- Concomitant use of drugs that can suppress cardiac contraction
- Whole body hyperthermia
- Female gender (mainly in children)

**Carcinogenicity:** Doxorubicin is carcinogenic in animals and is potentially carcinogenic in humans.
**Mutagenicity:** Mutagenic in the Ames test.³ Doxorubicin is clastogenic in mammalian *in vitro* and *in vivo* chromosome tests.⁷

**Fertility:** Treatment with doxorubicin may produce gonadal suppression, resulting in amenorrhea or azoospermia.¹¹

**Pregnancy:** Doxorubicin is classed as FDA Pregnancy Category D.²⁴ There is positive evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk. Chemotherapy protocols including Doxorubicin have been administered during pregnancy to treat breast cancer.²⁵ For more information please refer to The BC Cancer Agency Cancer Management Guidelines for Breast Cancer in Pregnancy.

**Breastfeeding** should not occur while a mother is undergoing chemotherapy with doxorubicin because Doxorubicin is secreted into breast milk.³,⁴

**SIDE EFFECTS:**

The table includes adverse events that presented during drug treatment but may not necessarily have a causal relationship with the drug. Because clinical trials are conducted under very specific conditions, the adverse event rates observed may not reflect the rates observed in clinical practice. Adverse events are generally included if they were reported in more than 1% of patients in the product monograph or pivotal trials, and/or determined to be clinically important.

<table>
<thead>
<tr>
<th>ORGAN SITE</th>
<th>SIDE EFFECT</th>
</tr>
</thead>
<tbody>
<tr>
<td>allergy/immunology</td>
<td>anaphylaxis may occur</td>
</tr>
<tr>
<td></td>
<td>fever, chills and urticaria (occasionally)</td>
</tr>
<tr>
<td>blood/bone marrow/febrile neutropenia</td>
<td>myelosuppression; especially leukopenia (75%)⁴ reaching nadir 10-14 days after treatment; recovery usually by day 21</td>
</tr>
<tr>
<td>cardiovascular (arrhythmia)</td>
<td>acute arrhythmia (0.5-3%); see paragraph following Side Effects table</td>
</tr>
<tr>
<td>cardiovascular (general)</td>
<td>acute transient ECG changes (20-30%); see paragraph following Side Effects table</td>
</tr>
<tr>
<td></td>
<td>delayed/late cardiotoxicity (18-65%); risk increases steeply with higher cumulative doses; see paragraph following Side Effects table</td>
</tr>
<tr>
<td>dermatology/skin</td>
<td>extravasation hazard: vesicant⁵</td>
</tr>
<tr>
<td></td>
<td>complete alopecia (up to 100%), regrowth occurs 2-3 months after discontinuing doxorubicin therapy⁶</td>
</tr>
<tr>
<td></td>
<td>facial flushing, if given too rapidly</td>
</tr>
<tr>
<td></td>
<td>hyperpigmentation of nail beds and dermal creases, soles, palms (1-10%); photosensitivity⁷</td>
</tr>
<tr>
<td></td>
<td>radiation recall reaction (hypersensitivity to irradiated skin); including redness, warmth, erythema and dermatitis in the radiation port (&lt;1%); endocrine</td>
</tr>
<tr>
<td>gastrointestinal</td>
<td>emetogenic potential: dose-related⁵: high-moderate for &gt; 60 mg/m², low-moderate for 20-60 mg/m², low for &lt; 20 mg/m²</td>
</tr>
<tr>
<td></td>
<td>anorexia (&gt;10%); diarrhoea (&gt;10%); mucositis; stomatitis and esophagitis (&gt;10%)⁴</td>
</tr>
</tbody>
</table>

Clinically important side effects are in **bold, italics**

<table>
<thead>
<tr>
<th>ORGAN SITE</th>
<th>SIDE EFFECT</th>
</tr>
</thead>
<tbody>
<tr>
<td>nausea and vomiting (21-55%)</td>
<td>dose related</td>
</tr>
<tr>
<td>ulceration and necrosis of colon (&gt;10%)</td>
<td></td>
</tr>
<tr>
<td>hepatic</td>
<td>changes in transaminase levels</td>
</tr>
<tr>
<td>metabolic/laboratory</td>
<td>hyperuricemia secondary to rapid tumour lysis of neoplastic cells, particularly when used in leukemia (1-10%)</td>
</tr>
<tr>
<td>ocular/visual</td>
<td>conjunctivitis and lacrimation (rarely)</td>
</tr>
<tr>
<td>renal/genitourinary</td>
<td>red colouration of urine for 1-2 days after administration (&gt;10%)</td>
</tr>
<tr>
<td>secondary malignancy</td>
<td>secondary acute myelogenous leukemia, acute lymphocytic leukemia</td>
</tr>
<tr>
<td>sexual/reproductive function</td>
<td>gonadal suppression resulting in amenorrhea or azospermia</td>
</tr>
</tbody>
</table>

Adapted from standard reference unless specified otherwise.

**Cardiotoxicity** is thought to be due to free radical damage as myocardial tissue is susceptible to these highly reactive species. Anthracycline cardiotoxicity may present with early or late effects. The following information applies to all anthracyclines, anthracenediones and mitoxantrone.

**Early cardiotoxic effects** are not dose-related and may present from mild ECG changes to life-threatening arrhythmias. These events may occur during or immediately after a single dose of anthracycline treatment, but do not predict subsequent development of delayed cardiotoxicity and are not considered indications for suspension of therapy.

**Late cardiotoxic effects**, which are dose-related and clinically the most important type of cardiotoxic effect, present as reduced LVEF or symptomatic CHF, and typically occur weeks to years after completion of treatment. Abnormalities in LVEF are associated with all the anthracyclines and their derivatives. LVEF changes are related to the total cumulative dose, are irreversible and refractory to medical therapy.

**Prevention and treatment:** Cardiac assessment should occur at baseline and throughout therapy. Monitor for symptomatic congestive heart failure (CHF) or reduced left ventricular ejection fraction (LVEF). Sensitive, non-invasive methods to measure LVEF include radionucleotide angiography (RNA), MUGA, or echocardiogram. Late cardiotoxic effects may be prevented by stopping treatment with the associated anthracycline once patients have reached the suggested maximum cumulative dose. Management of anthracycline cardiotoxicity includes discontinuation of the drug and initiating standard treatment of CHF.

Cardiotoxicity risk can be reduced but not eliminated with the use of alternative anthracyclines (i.e., epirubicin or liposomal doxorubicin) or by altering the frequency of administration (once a week vs. once every 3 weeks, or continuous infusion). Cardioprotectant therapy with dexrazoxane may be considered for patients with cumulative doxorubicin-equivalent doses greater than 300 mg/m².

Cumulative doses should be calculated using the following table, taking into account all previous anthracyclines or anthracenediones received during the patient’s lifetime.

<table>
<thead>
<tr>
<th>AGENT</th>
<th>SUGGESTED CONVERSION FACTOR TO DOXORUBICIN DOSE</th>
<th>SUGGESTED MONITORING THRESHOLD</th>
</tr>
</thead>
<tbody>
<tr>
<td>DAUNOrubicin</td>
<td>x 0.5-0.83</td>
<td>450 mg/m²</td>
</tr>
<tr>
<td>DOXOrubicin</td>
<td>x 1</td>
<td>300 mg/m²</td>
</tr>
</tbody>
</table>
**Hyperuricemia** may result from cell lysis by doxorubicin and may lead to electrolyte disturbances or acute renal failure.\[^{45}\] It is most likely with highly proliferative tumours of massive burden, such as leukemias, high-grade lymphomas, and myeloproliferative diseases. The risk may be increased in patients with preexisting renal dysfunction, especially ureteral obstruction. Suggested prophylactic treatment for high-risk patients\[^{36}\]:

- **aggressive hydration**: 3 L/m²/24 hr with target urine output >100 ml/h
- if possible, discontinue drugs that cause hyperuricemia (e.g., thiazide diuretics) or acidic urine (e.g., salicylates)
- monitor electrolytes, calcium, phosphate, renal function, LDH, and uric acid q6h x 24-48 hours
- replace electrolytes as required
- allopurinol 600 mg po initially, then 300 mg po q6h x6 doses, then 300 mg po daily x 5-7 days

Urine should be alkalized only if the uric acid level is elevated, using sodium bicarbonate IV or PO titrated to maintain urine pH>7. Rasburicase (FASTURTEC®) is a novel uricolytic agent that catalyzes the oxidation of uric acid to a water-soluble metabolite, removing the need for alkalization of the urine.\[^{47}\] It may be used for treatment or prophylaxis of hyperuricemia; however, its place in therapy has not yet been established. Aluminum hydroxide (AMPHOGEL®) may be added orally if phosphate becomes elevated. If aluminium hydroxide has been added, discontinue sodium bicarbonate.\[^{48}\]

**Local effects**: Extravasation of doxorubicin can occur with or without accompanying stinging or burning sensation, and even if blood returns well on aspiration of the infusion needle.\[^{3}\] Extravasation of doxorubicin will result in severe ulceration and soft tissue necrosis.\[^{4}\] To minimize the risk of thrombosis or perivenous extravasation, the dose should be infused over 3 to 10 minutes, depending on the vein size and the dose.\[^{7}\] For more information on prevention and treatment of extravasation with doxorubicin refer to BC Cancer Agency Provincial Systemic Therapy Program: Prevention and Management of Extravasation of Chemotherapy. Also, monitor for local erythematous streaking along vein and/or facial flushing which may indicate a too rapid infusion rate.\[^{4}\] This has traditionally been called the “doxorubicin flare.”\[^{49,50}\]

### INTERACTIONS:

<table>
<thead>
<tr>
<th>AGENT</th>
<th>EFFECT</th>
<th>MECHANISM</th>
<th>MANAGEMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>barbiturates[^{51}] (e.g., phenobarbital)</td>
<td>delayed, moderate possible; decreased pharmacological effects of doxorubicin</td>
<td>doxorubicin metabolism increased by barbiturates via CYP3A4 induction</td>
<td>monitor therapy</td>
</tr>
<tr>
<td>bevacizumab[^{21}]</td>
<td>doxorubicin-induced cardiotoxicity may be increased</td>
<td>unknown</td>
<td>monitor for increased cardiotoxicity (e.g., congestive heart failure)</td>
</tr>
<tr>
<td>calcium channel blockers[^{2}] (e.g., verapamil)[^{3}]</td>
<td>doxorubicin-induced cardiotoxicity may be increased</td>
<td>additive toxicity</td>
<td>monitor cardiac function throughout treatment</td>
</tr>
</tbody>
</table>

* based on relative hematological toxicities\[^{41}\]  
** Treatment may continue beyond these doses in selected patients, if the clinician has considered the potential risks and benefits. The addition of dexrazoxane may be considered, and monitoring should be increased. Maximum tolerated doses are variable; some patients may tolerate doxorubicin equivalent doses exceeding 1000 mg/m² while other patients exhibit symptomatic CHF at doxorubicin equivalent doses less than 300 mg/m².  

Hyperuricemia may result from cell lysis by doxorubicin and may lead to electrolyte disturbances or acute renal failure.\[^{45}\] It is most likely with highly proliferative tumours of massive burden, such as leukemias, high-grade lymphomas, and myeloproliferative diseases. The risk may be increased in patients with preexisting renal dysfunction, especially ureteral obstruction. Suggested prophylactic treatment for high-risk patients\[^{36}\]:

- **aggressive hydration**: 3 L/m²/24 hr with target urine output >100 ml/h
- if possible, discontinue drugs that cause hyperuricemia (e.g., thiazide diuretics) or acidic urine (e.g., salicylates)
- monitor electrolytes, calcium, phosphate, renal function, LDH, and uric acid q6h x 24-48 hours
- replace electrolytes as required
- allopurinol 600 mg po initially, then 300 mg po q6h x6 doses, then 300 mg po daily x 5-7 days

Urine should be alkalized only if the uric acid level is elevated, using sodium bicarbonate IV or PO titrated to maintain urine pH>7. Rasburicase (FASTURTEC®) is a novel uricolytic agent that catalyzes the oxidation of uric acid to a water-soluble metabolite, removing the need for alkalization of the urine.\[^{47}\] It may be used for treatment or prophylaxis of hyperuricemia; however, its place in therapy has not yet been established. Aluminum hydroxide (AMPHOGEL®) may be added orally if phosphate becomes elevated. If aluminium hydroxide has been added, discontinue sodium bicarbonate.\[^{48}\]

**Local effects**: Extravasation of doxorubicin can occur with or without accompanying stinging or burning sensation, and even if blood returns well on aspiration of the infusion needle.\[^{3}\] Extravasation of doxorubicin will result in severe ulceration and soft tissue necrosis.\[^{4}\] To minimize the risk of thrombosis or perivenous extravasation, the dose should be infused over 3 to 10 minutes, depending on the vein size and the dose.\[^{7}\] For more information on prevention and treatment of extravasation with doxorubicin refer to BC Cancer Agency Provincial Systemic Therapy Program: Prevention and Management of Extravasation of Chemotherapy. Also, monitor for local erythematous streaking along vein and/or facial flushing which may indicate a too rapid infusion rate.\[^{4}\] This has traditionally been called the “doxorubicin flare.”\[^{49,50}\]
<table>
<thead>
<tr>
<th>AGENT</th>
<th>EFFECT</th>
<th>MECHANISM</th>
<th>MANAGEMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>cyclophosphamide&lt;sup&gt;4&lt;/sup&gt;</td>
<td>doxorubicin-induced cardiotoxicity may be increased</td>
<td>additional myocardial cell damage</td>
<td>caution, but combination regime is commonly used</td>
</tr>
<tr>
<td>cyclophosphamide&lt;sup&gt;3&lt;/sup&gt;</td>
<td>cyclophosphamide-induced hemorrhagic cystitis may be increased</td>
<td>unknown</td>
<td>caution</td>
</tr>
<tr>
<td>cyclosporine&lt;sup&gt;52&lt;/sup&gt;</td>
<td>increased pharmacological effects of doxorubicin</td>
<td>doxorubicin metabolism decreased by cyclosporine either by competition for CYP3A4 or p-glycoprotein inhibition</td>
<td>consider therapy modification</td>
</tr>
<tr>
<td>digoxin tablets&lt;sup&gt;53&lt;/sup&gt;</td>
<td>delayed, moderate, suspected; decreased pharmacological effects of digoxin</td>
<td>digoxin absorption decreased by antineoplastic agents due to alteration of intestinal mucosa</td>
<td>monitor for decreased effect of digoxin</td>
</tr>
<tr>
<td>mercaptopurine&lt;sup&gt;4&lt;/sup&gt;</td>
<td>increased mercaptopurine hepatotoxicity&lt;sup&gt;5&lt;/sup&gt;</td>
<td>unknown</td>
<td>monitor therapy</td>
</tr>
<tr>
<td>paclitaxel&lt;sup&gt;54&lt;/sup&gt;</td>
<td>increased doxorubicin pharmacological effects&lt;sup&gt;4&lt;/sup&gt;</td>
<td>doxorubicin clearance decreased either by competition for CYP3A4 or p-glycoprotein</td>
<td>monitor for increased cardiotoxicity (e.g., congestive heart failure) or consider using docetaxel instead of paclitaxel&lt;sup&gt;54&lt;/sup&gt;</td>
</tr>
<tr>
<td>quinolones&lt;sup&gt;51&lt;/sup&gt; (e.g., ciprofloxacin)</td>
<td>delayed, moderate, possible; the antimicrobial effect of quinolones may be decreased</td>
<td>quinolone absorption decreased by antineoplastic agents due to alteration of intestinal mucosa</td>
<td>monitor therapy</td>
</tr>
<tr>
<td>stavudine&lt;sup&gt;55&lt;/sup&gt;</td>
<td>decreased pharmacological effects of stavudine</td>
<td>stavudine metabolism to active drug is decreased by doxorubicin due to inhibition of phosphorylation</td>
<td>avoid concomitant use</td>
</tr>
<tr>
<td>streptozocin&lt;sup&gt;4&lt;/sup&gt;</td>
<td>greatly enhanced leukopenia and thrombocytopenia</td>
<td>doxorubicin half life possibly prolonged&lt;sup&gt;11&lt;/sup&gt;</td>
<td>caution</td>
</tr>
<tr>
<td>trastuzumab&lt;sup&gt;56&lt;/sup&gt;</td>
<td>increased cardiotoxicity</td>
<td>unknown</td>
<td>consider therapy modification</td>
</tr>
</tbody>
</table>

Doxorubicin is a major CYP2D6 substrate therefore drugs that are CYP2D6 inhibitors (e.g., chlorpromazine, paroxetine, quinine) could potentially increase the pharmacological effects of doxorubicin.<sup>7</sup> Doxorubicin is a major CYP3A4 substrate therefore drugs that are CYP3A4 inducers (e.g., carbamazepine, phenytoin, St John’s wort) could potentially decrease the pharmacological effects of Doxorubicin.<sup>4</sup> CYP3A4 inhibitors (e.g., didlofenac, imatinib, verapamil) could potentially increase the pharmacological effects of Doxorubicin.<sup>5</sup>

Doxorubicin is a moderate CYP2B6 inhibitor therefore could potentially increase the pharmacological effects of drugs that are CYP2B6 substrates (e.g., promethazine, propofol, selegiline).<sup>4</sup> Doxorubicin is also a weak CYP2D6 inhibitor and a weak CYP3A4 inhibitor.<sup>4</sup>

**SUPPLY AND STORAGE:**
**Injection**: Mayne Pharma supplies doxorubicin in single-dose vials of sterile, preservative-free, lyophilized red powder of 10 mg, 50 mg and 150 mg sizes. The formulation contains lactose. Store vials between 15-20ºC and protect from light (keep intact vials in their carton until use).

Novopharm supplies doxorubicin in single-dose vials of sterile, isotonic, preservative-free solution of 10 mg/5 mL, 50 mg/25 mL and 200 mg/100 mL sizes. The formulation contains hydrochloric acid for pH adjustment. Refrige rate vials and protect from light (keep intact vials in their carton until use).

Pfizer supplies doxorubicin in single-dose vials of sterile, isotonic, preservative-free solution of 10 mg/5 mL, 50 mg/25 mL and 200 mg/100 mL sizes. The formulation contains hydrochloric acid for pH adjustment. Refrigerate vials and protect from light (keep intact vials in their carton until use).

*For basic information on the current brand used at the BC Cancer Agency, see [Chemotherapy Preparation and Stability Chart](#) in Appendix.*

**SOLUTION PREPARATION AND COMPATIBILITY:**

*For basic information on the current brand used at the BC Cancer Agency, see [Chemotherapy Preparation and Stability Chart](#) in Appendix.*

**Additional information:**
- **Aluminum** metal interacts with doxorubicin solution producing a darker colour solution and a possible precipitation of drug. Aluminum-containing apparatus should not be used in the preparation or administration of doxorubicin.

**PARENTERAL ADMINISTRATION:**

| Subcutaneous | not used due to corrosive nature |
| Intramuscular | not used due to corrosive nature |
| **Direct intravenous** | Preferred method due to need for frequent monitoring for signs of extravasation: via small (21 or 23) gauge needle into tubing of running IV. Push slowly, so that drip of IV solution does not stop or reverse. Check for blood return before administration and after every 2-3 mL of drug. If no blood return, stop the injection and assess the IV site. Flush with 20 mL NS or D5W after administration to clear any remaining drug from tubing. |
| Intermittent infusion | has been used |
| Continuous infusion | has been used |
| Intraperitoneal | hyperthermic intraperitoneal chemotherapy (HIPEC): pump solution into abdominal cavity and circulate as per protocol using hyperthermia pump; solutions and dwell time vary by protocol |
| Intrapleural | has been used |
| Intrathecal | no information found |
| Intr-arterial | has been used |
| Intravesical | induction doses of 50-80 mg in 50-100 mL NS have been used weekly for 4 weeks, followed by monthly maintenance doses for 1 year or longer; solutions are retained for 1-2 h after instillation |
DOXOrubicin

**DOSAGE GUIDELINES:**

Refer to protocol by which patient is being treated. Numerous dosing schedules exist and depend on disease, response and concomitant therapy. Guidelines for dosing also include consideration of absolute neutrophil count (ANC). Dosage may be reduced, delayed or discontinued in patients with bone marrow depression due to cytotoxic/radiation therapy or with other toxicities.

**Adults:**  
BCCA usual dose noted in **bold, italics**

| Cycle Length: |  
|-------------|---|
| **Intravenous:** |  
| 1 week[^f]: | 25 mg/m² IV for one dose on day 1  
(total dose per cycle 25 mg/m²) |
| 1 week[^g]: | 15-20 mg IV for one dose on day 1  
(total dose per cycle 15-20 mg) |
| 2 weeks[^h]: | 60 mg/m² IV for one dose on day 1  
(total dose per cycle 60 mg/m²) |
| 3 weeks[^10,16-18,68-89]: | 40-75 mg/m² IV for one dose on day 1  
(total dose per cycle 40-75 mg/m²) |
| 4 weeks[^92]: | 50 mg/m² IV for one dose on day 1  
(total dose per cycle 50 mg/m²) |
| 4 weeks[^97]: | 30 mg/m² IV for one dose on day 2  
(total dose per cycle 30 mg/m²) |
| 4 weeks[^92]: | 30 mg/m² IV for one dose on days 1 and 8  
(total dose per cycle 60 mg/m²) |
| 4 weeks[^93,94]: | 25-30 mg/m² IV for one dose on days 1 and 15  
(total dose per cycle 50-60 mg/m²) |
| 6 weeks[^12,13]: | 75 mg/m² IV for one dose on day 1  
(total dose per cycle 75 mg/m²) |
| 8 weeks[^96]: | 50 mg/m² IV for one dose on day 1  
(total dose per cycle 50 mg/m²) |

**Suggested maximum cumulative doses:**  
3 week cycle: 550 mg/m²  
1 week cycle: 700 mg/m²[^3,7,22]  
If risk factors are present:  
3 week cycle: 400-450 mg/m²[^3,7,22,23]  
1 week cycle: 550 mg/m²[^3,7,22]

**Concurrent radiation:** not recommended[^67] however in the BC Cancer Agency Protocol SAAJA[^96] selected patients may receive

**Dosage in obese patients[^7]:** consider lower starting doses or longer intervals between cycles

**Dosage in myelosuppression:** modify according to protocol by which patient is being treated; if no guidelines available, refer to Appendix "Dosage Modification for Myelosuppression"

**Dosage in renal failure:** no adjustment required[^4]
**DOXOrubicin**

BCCA usual dose noted in **bold, italics**

**Cycle Length:**

**Dosage in hepatic failure:**

<table>
<thead>
<tr>
<th>ALT/AST</th>
<th>Bilirubin (micromol/L)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>2-3 x ULN</td>
<td>-</td>
<td>75%</td>
</tr>
<tr>
<td>&gt; 3 x ULN</td>
<td>20-50</td>
<td>50%</td>
</tr>
<tr>
<td>&gt; 51</td>
<td>25%</td>
<td></td>
</tr>
<tr>
<td>&gt; 85</td>
<td>Do not administer</td>
<td></td>
</tr>
</tbody>
</table>

**Dosage in dialysis:**

- hemodialysis: supplemental dose not required
- chronic ambulatory peritoneal dialysis (CAPD): no data
- continuous arteriovenous or venous hemofiltration (CAVH): dose for GFR 10-50 mL/min

**Children:**

**Intravenous:**

<table>
<thead>
<tr>
<th>Type</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td>45-90 mg/m² IV continuous infusion (24-96 h)</td>
</tr>
<tr>
<td>N/A</td>
<td>30-45 mg/m² IV daily x 3 or weekly</td>
</tr>
<tr>
<td>1 week</td>
<td>20-30 mg/m² IV for one dose on day 1 (total dose per cycle 20-30 mg/m²)</td>
</tr>
<tr>
<td>3 weeks</td>
<td>40-75 mg/m² IV for one dose on day 1 (total dose per cycle 40-75 mg/m²)</td>
</tr>
</tbody>
</table>

**REFERENCES:**


BC Cancer Agency Cancer Drug Manual© Page 9 of 12

Developed: September 1994
Revised: 1 February 2017


35. Pfizer Canada Inc. IDAMYCIN® product monograph. Kirkland, Quebec; 19 February 2009.


BC Cancer Agency Cancer Drug Manual© Page 11 of 12

DOXOrubicin

58. Pharmacia Limited. Pharmorubicin Solution for Injection® product monograph. Sandwich, Kent (United Kingdom); 15 September 2010.
59. Actavis UK Ltd. Epirubicin hydrochloride injection® product monograph. Barnstaple, Devon (United Kingdom); 12 April 2011.